机构：[1]Cancer Center, TCM-Integrated Hospital, Southern Medical University, Guangzhou , Guangdong, PR China[2]Peking University Shenzhen Hospital, Shenzhen, PR China北京大学深圳医院深圳医学信息中心[3]Dpartment of Pathology, School of Basic Medicine,Guangzhou Medical College, Guangzhou, PR China[4]Cancer Research Institute, Southern Medical University,Guangzhou, PR China
出处：
ISSN：
摘要：
To examine the expression pattern of CCND1 and analyze the correlation of its nuclear expression with clinicopathologic features and prognosis in lung adenocarcinoma.
CCND1 mRNA and protein levels in lung adenocarcinoma tissues were examined. The relationship between nuclear CCND1 protein expression and clinical features including survival prognosis was analyzed.
CCND1 mRNA levels were markedly increased in lung adenocarcinoma (P=0.0019). Western blot analysis confirmed increased nuclear CCND1 protein expression in lung adenocarcinoma specimens. Immunohistochemistry analysis confirmed that CCND1 protein was predominantly nuclear localized in lung adenocarcinoma cells and significantly elevated relative to normal lung tissues (P<0.001). Furthermore, high levels of nuclear CCND1 were positively correlated with clinical stage (P=0.026). Patients with nuclear CCND1 expression had a significantly shorter overall survival time than did patients with low expression. Interestingly, nuclear CCND1 expression in clinical stage I+II, but not clinical stage III, was shown associated with poor prognosis and shorter overall survival time for lung adenocarcinoma patients by strata analysis. Finally, nuclear CCND1 expression tended to be an independent prognostic indicator (P=0.087) for lung adenocarcinoma patient survival.
Increased nuclear CCND1 is a potential unfavorable prognostic factor for lung adenocarcinoma patients, especially those with clinical early stage (stage I+II).
基金：
This study was supported by New Star Plan
of Pearl River Science and Technology
from Guangzhou City (No. 2011J2200009),
Guangdong Province Breeding Project Plan
(No. LYM11102), Educational Commission of
Guangdong province, China (Grant No.
cxad1120) and Technology and Information
Bureau of Guangzhou City (No. 2010Y1-C231).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2014]版：
大类|4 区医学
小类|4 区肿瘤学4 区病理学
最新[2025]版：
大类|4 区医学
小类|4 区肿瘤学4 区病理学
第一作者：
第一作者机构：[1]Cancer Center, TCM-Integrated Hospital, Southern Medical University, Guangzhou , Guangdong, PR China[2]Peking University Shenzhen Hospital, Shenzhen, PR China
共同第一作者：
通讯作者：
通讯机构：[1]Cancer Center, TCM-Integrated Hospital, Southern Medical University, Guangzhou , Guangdong, PR China[4]Cancer Research Institute, Southern Medical University,Guangzhou, PR China[*1]Cancer Center, TCM-Integrated Hospital, Southern Medical University, Guangzhou 510310, Guangdong, China[*2]Cancer Research Institute, Southern Medical University, Guangzhou 510515, PR China[*3]Cancer Center, TCM-Integrated Hospital, Southern Medical University, Guangzhou 510310, Guangdong, PR China
推荐引用方式(GB/T 7714)：
Xu Ping,Zhao Mengyang,Liu Zhen,et al.Elevated nuclear CCND1 expression confers an unfavorable prognosis for early stage lung adenocarcinoma patients.[J].International journal of clinical and experimental pathology.2015,8(12):15887-94.
APA：
Xu Ping,Zhao Mengyang,Liu Zhen,Liu Yiyi,Chen Yiyu...&Fang Weiyi.(2015).Elevated nuclear CCND1 expression confers an unfavorable prognosis for early stage lung adenocarcinoma patients..International journal of clinical and experimental pathology,8,(12)
MLA：
Xu Ping,et al."Elevated nuclear CCND1 expression confers an unfavorable prognosis for early stage lung adenocarcinoma patients.".International journal of clinical and experimental pathology 8..12(2015):15887-94
